By Peter Nurse
Investing.com — Stocks in focus in premarket trade on Monday, June 21th. Please refresh for updates.
Amazon (NASDAQ:AMZN) stock rose 0.2% after the e-commerce giant started its two-day Prime Day, a sales event which generated $10.4 billion in gross merchandise sales last year.
Raven (NASDAQ:RAVN) Industries stock rose over 48% after the manufacturer of precision agriculture products accepted an offer from CNH Industrial (NYSE:CNHI) of $2.1 billion, with the deal expected to close in the fourth quarter.
Coinbase Global (NASDAQ:COIN) stock fell 3% with investors leaving the cryptocurrency platform after China expanded its clampdown on Bitcoin mining. MicroStrategy (NASDAQ:MSTR) stock fell 7.8%, as the business analytics company is one of the largest corporate investors in bitcoin.
CureVac (NASDAQ:CVAC) stock rose 3.4% after the scientist leading the study into the drug maker’s Covid-19 vaccine said the reason it only proved 47% effective may be down to low dosage.
GameStop (NYSE:GME) stock rose 1.5% after the troubled video game retailer named Chief Executive Officer Matt Furlong to its board, the same day the former Amazon executive is set to take charge of the company.
Theravance Biopharma (NASDAQ:TBPH) stock fell 6.3% after the company announced a drug it was developing to treat Covid-19-related lung injury failed to meet the standards.
American Airlines (NASDAQ:AAL) stock rose 0.4% after the airline announced plans to cancel around 1% of its flights in July as it struggles to cope with a sharp uptick in travel demand.
Ziprecruiter (NYSE:ZIP) stock rose 3% after Goldman Sachs initiated coverage of the online recruitment agency at ‘buy’, saying it is well positioned to benefit from the move in recruitment online.
Pershing Square Tontine Holdings (NYSE:PSTH) stock rose 1.3% after the SPAC controlled by Bill Ackman finalized a deal to buy a 10% stake in Universal Music from Vivendi (OTC:VIVHY).
Amazon, CureVac Rise Premarket; Coinbase Global Falls
GameStop names CEO Matt Furlong to board
Germany’s BaFin looking into possible insider trading of CureVac shares